09
Aug
A growing trend in the use of GLP-1 receptor agonists for weight loss involves a practice known as "microdosing." This experimental approach, which entails taking a lower-than-prescribed dose of these popular medications, is being adopted by some patients in an attempt to manage side effects, reduce costs, or achieve more gradual weight loss. However, this strategy is not without significant debate, and medical professionals are carefully weighing the potential benefits against a number of substantial risks.The interest in microdosing is mainly fueled by an intention to reduce the typical, and sometimes intense, stomach-related side effects linked with the usual therapeutic…